The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK).
 
Michaël Duruisseaux
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Guardant Health; Janssen; Sanofi; Takeda
Travel, Accommodations, Expenses - Novartis; Takeda
 
Aurélie Swalduz
Honoraria - Amgen; AZD; Boehringer Ingelheim; Roche
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Janssen; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Janssen
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Elodie Amour
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Virginie Westeel
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; MSD Oncology; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb; MSD Oncology